SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC
IPIC 0.00010000.0%Dec 18 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: (no name provided) who wrote (765)10/2/1997 1:33:00 PM
From: WeirdPro Randy   of 1359
 
I do not believe NeuroInvestment missed the point at all......I certainly don't see him trying to suggest Redux will ever return to the market.
I also see differences between Redux and the breast implant issue, and does relate with points discussed by NeuroInvestment............Most importantly, breast implants differ greatly from Redux on a "risk vs. reward" basis, in that the implants were used for a predominantly cosmetic condition vs. Redux treating a medically "threatening" condition ( at least when utilized as per indications).......even before the heart valve problem began, doctors and patients had to weigh this, as a potential known side effect was death. But the reward was reduction from a condition which also carried severe risks, including death.......
What is the risk of "small breasts" (or the reward of "large breasts"), certainly the predominant use for the breast implant.
The liability, or potential for damage rewards, of a patient death during routine dental procedures is significantly greater than a patient death during bypass surgery (sorry to dentists for this analogy).
Doctors and patients are already decrying the loss of the diet drugs (which prior to more data is probably premature), based on the loss of a treatment regimen for a deadly disease.........who cried out when silicone breast implants were no longer available?

Also,as you write<< AHP can afford the suits and potential settlements. IPIC will go bankrupt on lawyer's fees alone.>>.....It interests me how the different lawsuits are/will actually be structured........you are dealing with two different products involving two separate litigants, each product with potentially differing causality and damage potential (ie if causality relates with time frame usage......Redux may be significantly reduced in implication as it was only available for a little over one year, .....and we don't even have a breakdown on which drugs these 30+% with valvular disease relate with other).........but what lawyer is going to spend millions to sue a company which will be bankrupt on lawyer's fees alone?
Finally as you write<<No, it won't make any difference whether they "voluntarily" withdrew the drugs in terms of liability.>>,,,,,disagree, the prudence and timeliness of IPIC's action would have definite mitigating repercussions, esp. in the eyes of a jury or in negotiating a settlement, should it ever come to that.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext